Diakron Pharmaceuticals Inc., Merck, Orchid Chemicals & Pharmaceuticals deal

Diakron received an exclusive, worldwide license from Merck to develop and market DP-4088 for any indication. Diakron will develop the compound as an anticoagulant. The oral, small-molecule thrombin inhibitor completed a Phase I trial in healthy volunteers. Merck will receive an undisclosed upfront fee and is eligible for milestones and royalties. ...